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Abstract
We have previously shown that the chemokine fractalkine
promotes the adhesion of human prostate cancer cells to bone
marrow endothelial cells as well as their migration toward
human osteoblasts in vitro. Thus, the interaction of fractalkine
with its receptor CX3CR1 could play a crucial role in vivo by
directing circulating prostate cancer cells to the bone. We
found that although CX3CR1 is minimally detectable in epi-
thelial cells of normal prostate glands, it is overexpressed
upon malignant transformation. Interestingly, osteoblasts,
stromal and mesenchymal cells derived from human bone
marrow aspirates express the cell-bound form of fractalkine,
whereas the soluble form of the chemokine is detected in bone
marrow supernatants. To investigate the mechanisms regu-
lating the levels of soluble fractalkine in the bone marrow,
we focused on androgens, which play a critical role in both
prostate cancer progression and skeletal metastasis. Here,
we show that dihydrotestosterone dramatically increases the
cleavage of fractalkine from the plasma membrane of bone
cells and its action is reversed by nilutamide—an antagonist
of the androgen receptor—as well as the wide-spectrum inhi-
bitor of matrix metalloproteases, GM6001. However, dihydro-
testosterone was unable to induce fractalkine-cleavage from
human bone marrow endothelial cells. Thus, androgens could
promote the extravasation of CX3CR1-bearing cancer cells
on a fractalkine concentration gradient, while leaving unal-
tered their ability to adhere to the bone marrow endothelium.
In conclusion, our results indicate that CX3CR1, fractalkine,
and the enzymes responsible for its cleavage might represent
suitable targets for therapies aiming to counteract skeletal
secondary tumors from prostate adenocarcinoma. [Cancer Res
2008;68(6):1715–22]
Introduction
The mechanisms by which cancer cells traveling through the
circulatory system arrest into distant organs are still a matter of
debate. However, it is likely that in addition to vascular patterns,
unique characteristics of the endothelial cells lining the capillary
beds of the colonized tissues play a role in cancer organ-tropism
(1, 2). For instance, specific adhesion macromolecules might be
expressed only by compatible cancer and endothelial cells, thus
promoting the preferential, albeit not exclusive, arrest of cancer
cells into a specific tissue. However, simply adhering to the
endothelial wall will not suffice to invade an organ. Thus, similar to
leukocytes and hematopoietic stem cells, cancer cells may migrate
from the luminal side of the endothelial cells into the surrounding
tissue in response to chemotactic molecules released by stromal
cells. Chemokines—a family of chemotactic cytokines composed of
more than 45 members (3, 4)—have been implicated in both the
adhesion and extravasation of disseminated cancer cells (5). For
instance, a recent seminal article shows that CXCL12/SDF-1a—by
signaling through its receptor CXCR4—is involved in chemotactic
and invasive responses of breast cancer cells in vitro and their
induction of lung metastases in a mouse model (6).
The SDF-1/CXCR4 pair seems to exert a predominant role in
cancer cell migration and chemoattraction, and its effect on the
adhesion of cancer cells to bone marrow endothelium has also
been proposed. However, because SDF-1 is a soluble chemokine, its
presentation to circulating cancer cells must depend on its binding
to cellular proteoglycans located on the surface of endothelial cells
(7). Although this mechanism seems to be widely accepted (8–11),
the resistance to the shear stress of the blood flow offered by SDF-1
while tethered to the endothelial wall raises some concerns (12).
In addition, the proadhesive effect of SDF-1 is exerted indirectly, by
inducing the expression of integrins and VCAM-1 through CXCR4
activation, similar to melanoma and small cell lung cancer cells
(10, 13). Unlike SDF-1, fractalkine possesses intrinsic cell-adhesive
properties and is constitutively expressed by human bone marrow
endothelial (HBME) cells as a trans-membrane protein (14), an
ideal feature to withstand the shear forces of the blood flow.
In fact, immune cells expressing CX3CR1 directly bind and firmly
adhere to fractalkine anchored to the surface of endothelial cells
(15, 16). Interestingly, we have recently shown that human prostate
cancer cells—studied in a dynamic adhesion assay and under
physiologic flow conditions—attach to bone marrow endothelial
cells in a fractalkine-dependent fashion (17). Furthermore, we
found that fractalkine is also expressed by human osteoblasts in
culture, which can cleave and release it into its soluble form and
chemoattract prostate cancer cells in vitro (17). These results
suggest that CX3CR1 and fractalkine could play a role in the
prostate cancer cell adhesion and extravasation steps of skeletal
metastasis; therefore, we decided to foster the translational
significance of these previous observations by investigating the
expression of this chemokine/receptor pair in prostate gland tissue
specimens and bone marrow aspirates from human donors.
This study also aimed to determine whether the cleavage of
fractalkine in its soluble form by human bone marrow cells could
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Research Articlebe regulated by androgens. A recent clinical trial shows that the
inhibitor of the androgen receptor bicalutamide induces a 33%
reduction in the incidence of bone metastases in patients with
localized or locally advanced prostate cancer (18), a likely con-
sequence of the fact that bicalutamide negatively affects the
survival of androgen-dependent cancer cells. As the androgen
receptor is expressed by bone cells including osteoblasts (19–21),
its activation could increase fractalkine cleavage and availability
in the marrow stroma—by stimulating members of the ADAM
matrix metalloproteinases (MMP) family (22, 23)—thereby pro-
moting the establishment of a chemoattractant gradient for
CX3CR1-expressing cells. Consequently, inhibition of the androgen
receptor in cells of the bone marrow could also reduce fractalkine
cleavage, thereby counteracting the extravasation of prostate
cancer cells into the bone microenvironment.
Materials and Methods
Cell lines and cell cultures. The human bone marrow mesenchymal
stem cells (hMSC), human bone stromal cells (hBSC), and normal human
osteoblasts (NHOst)—all from male donors—were from Lonza Walkersville,
Inc. The HBME-1 cells—originally isolated from a male donor by the group
of Dr. Pienta (24)—were a gift from Dr. Mark Stearns (Drexel University
College of Medicine, Philadelphia, PA). The hMSC were grown in medium
containing 10% mesenchymal cell growth supplements, 2% L-glutamine,
and 0.1% penicillin/streptavidin in mesenchymal stem cell basal medium
(Lonza Walkersville, Inc.). The hBSC were grown in a-MEM containing 25%
fetal bovine serum (FBS), 1% a-inositol, 1% h-mercaptoethanol, 1% folic
acid, and 0.1% gentamicin. The NHOst were grown in osteoblast basal
medium, containing 10% of FBS, 0.1% ascorbic acid, and 0.1% gentamicin in
osteoblast basal medium (Lonza Walkersville, Inc.). The HBME-1 cells were
grown in medium-199 containing 10% FBS, 10% human serum (Wisent,
Inc.), and 1 ng/mL of h-fibroblast growth factor, 5 units/mL of heparin
(Sigma-Aldrich), and 0.1% gentamicin.
Immunohistochemistry and tissue array analysis. Tissue microarrays
were obtained from U.S. Biomax, Inc. For the detection of human CX3CR1,
we used tissue arrays containing cores from 156 different cases of prostate
adenocarcinoma, 10specimens of normal tissue adjacent to cancer, and
31 normal prostate glands in total (PR802, PR242, PR483, PR951, PR481,
and BC19111). For the detection of human fractalkine, we used an array
containing bone marrow tissue cores from 27 different donors ranging from
30to 75 years of age (PR80 2). Tissue arrays were deparaffinized with
Histosolve (Dako Cytomation) and rehydrated with decreasing concen-
trations of ethanol. Endogenous peroxidase was quenched using methanol
and hydrogen peroxide. Antigen retrieval was performed using DakoCyto-
mation Target Retrieval Solution in a 95jC water bath for 30minutes.
Arrays were first blocked with 10% normal donkey serum in TBS for
60minutes and then incubated in either antihuman CX3CR1 (Abcam 720 1)
at 3.3 Ag/mL or antihuman fractalkine (R&D Systems AXV02) at 10 Ag/mL
in TBS at 4jC overnight. Primary antibody binding was detected using
either biotin-conjugated donkey anti-rabbit or biotin-conjugated donkey
anti-goat (Jackson ImmunoResearch), respectively, at 20 Ag/mL in TBS for
2 hours. Signals were amplified with Vectastatin Elite ABC kit and vis-
ualized using the chromogenic visualization 3,3¶-diaminobenzidine kit
(Vector Laboratories). The tissue arrays were then dehydrated using increas-
ing concentrations of ethanol and Histosolve. Permount solution (Fisher
Scientific) was used for mounting.
Processed microarrays were examined using two different approaches:
(a) tissue core staining was quantified and analyzed by acquiring a digital
image of the entire array and processing it using the Metamorph software
(Molecular Devices). Color images were converted to 8-bit gray scale images
and gray pixel values from negative controls (primary antibody omitted)
were averaged and subtracted from the gray level reading of each specimen
exposed to the primary antibody; (b) cellular staining for each specimen
was evaluated by light microscopy, using a Nikon Optiphoto-2 microscope
connected to an Olympus DP-70CCD color camera. For CX3CR1 detection,
staining intensity was scored based on a scale in which negative specimens
were graded 0and strongly positive samples were graded 3 (also see Table 1).
All the images were acquired using identical lamp settings and a shutter
speed of 1/350seconds without averaging.
Confocal microscopy. Cells were grown on 15 mm glass coverslips and
fixed using a pH shift formaldehyde protocol, to avoid cell shrinkage and
preserve the three-dimensional cellular organization. The same antibody
used for Western blotting against fractalkine was employed for confocal
microscopy analysis. A CY3-conjugated secondary antibody (Jackson
ImmunoResearch), was used to detect the primary antibody. Samples were
imaged using a Nikon PCM 2000 connected to a Nikon Diaphot 300 inverted
microscope mounting a 60 1.40numerical aperture oil immersion
objective. Images were collected using a step size of 0.5 Am along the z
axis and at a resolution of 1,280  1,280using the C-Imaging software.
Cell treatment with androgens and inhibitors. Cells were grown to
f90% confluence in their respective media. Prior to being exposed to
dihydrotestosterone, used at 100 nmol/L, cells were moved in a culture
medium containing charcoal-stripped FBS for 12 to 24 hours. For the
experiments involving pharmacologic inhibitors, cells were preincubated for
30minutes with either the androgen receptor inhibitor nilutamide (Sigma-
Aldrich), used at 1 Amol/L, or the MMP inhibitor GM-6001 (Chemicon),
used at 25 Amol/L, before treatment with dihydrotestosterone.
SDS-PAGE and Western blotting. Cell lysates were obtained using a
lysis buffer containing Igepal CA-630and DTT (Sigma), phosphatase, and
protease inhibitor cocktails (Calbiochem). Protein concentrations of cellular
lysates were determined using the bicinchoninic acid protein assay (Pierce).
Samples containing equivalent amounts of proteins were resolved by SDS-
PAGE using 10% polyacrylamide gels. The proteins were transferred onto
Immobilon polyvinylidene difluoride membranes (Millipore Corporation).
Membranes were then incubated in blocking buffer containing 25% non–
animal protein blockers (Genotech) and 0.1% Tween 20 in TBS for 1 hour at
room temperature. The membranes were then incubated overnight at 4jC
with a rabbit polyclonal anti-fractalkine antibody specific for the
chemotactic domain of human fractalkine (Torrey Pines Biolabs) at a
concentration of 1 Ag/mL in TBS containing 0.1% Tween 20. Horseradish
peroxidase–conjugated protein A (Sigma-Aldrich) was used at 0.1 Ag/mL to
detect the primary antibody. Signal was detected using SuperSignal West
Femto chemiluminescence reagents (Pierce) and visualized with a
FluorChem imaging system (Alpha Innotech).
Detection of soluble fractalkine. Fractalkine in both human bone
marrow aspirates and cellular supernatants were detected using the ELISA
DuoSet kit (R&D Systems), after removal of the cellular fraction and as
suggested by the manufacturer. Briefly, plates were coated and incubated
overnight with the capture antibody at 4 Ag/mL in saline solution. After
washing and the addition of blocker (1% bovine serum albumin) the
samples were added to the wells. The biotinylated detection antibody was
used at 500 ng/mL, followed by streptavidin-horseradish peroxidase.
A tetramethylbenzidine substrate solution was incubated for 30minutes
to detect the streptavidin bound to the detection antibody. The chromo-
genic reaction was then stopped with 50 AL of sulfuric acid and absorbance
determined at 450nm with correction set to 570nm. A standard curve was
generated using fractalkine as purified recombinant protein and sample
concentrations were calculated using a linear regression equation.
Statistical analysis. Experimental results are expressed as mean F SE.
Statistical significance was determined with the one-way ANOVA test.
Statistical significance was assumed at P V 0.05.
Results and Discussion
We hypothesize that circulating prostate cancer cells are able to
locate to the bone marrow using a mechanism similar to that used
by leukocytes migrating to inflamed tissues and involving CX3CR1
and its ligand fractalkine expressed on the surface of prostate and
endothelial cells, respectively. A further step in the metastatic cas-
cade could then be completed when prostate cancer cells adher-
ing to the bone marrow endothelium respond to a gradient of
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into the bone microenvironment. Fractalkine, in its soluble form—
after being cleaved from the surface of bone marrow cells—could
likely be involved in this process, as we have previously shown by
an in vitro chemotaxis approach (17). To emphasize the clinical
relevance of our model, we investigated CX3CR1 and fractalkine
expression in human samples of prostate gland and bone marrow,
respectively.
A first set of experiments was conducted to establish whether
the CX3CR1 receptor for fractalkine was expressed by ex vivo
specimens and employed microarrays assembled with tissue cores
of prostate glands that were either normal or affected by adeno-
carcinoma. CX3CR1 expression was observed in normal prostate
tissues, although the highest levels of signal intensity were detected
exclusively in specimens from malignant glands (Table 1). The
expression of CX3CR1 by the epithelial cells was confirmed by light
microscopy (Fig. 1A–C; Supplementary Data 1); the specificity of
the antibody used in this study for CX3CR1 was validated by the
lack of staining observed in human tissue samples from heart, com-
bined with the strong signal detected in samples of human lung, in
agreement with previous studies by others (ref. 25; Supplementary
Data 1).
These results suggest that the expression of the CX3CR1 chemo-
kine receptor is a common feature of the prostate epithelium—as
we previously reported using primary prostate cells in culture
(17)—although malignant transformation seems to increase its
expression levels (Table 1). Interestingly, specimens of morpholog-
ically normal prostate gland adjacent to cancer tissue were always
found positive for CX3CR1 (Table 1). However, a relevant number
of specimens from both normal and malignant prostate stained
negative for CX3CR1. This could be due to histologic heterogeneity
and different areas of the same gland might display diverse
patterns of CX3CR1 expression. However, it could be alternatively
hypothesized that CX3CR1 expression is a feature of selected
Table 1. Intensity and distribution of CX3CR1 detection in either normal, adjacent to cancer, or malignant prostate gland
tissues
Tissues 0 0–1 1–2 2–3 Total
Normal 17 9 5 031
Adjacent to cancer 02 8 0 10
Malignant 53 32 54 17 156
NOTE: Staining intensity was scored based on a scale in which negative specimens were graded (0) and strongly positive samples were graded (3). To
evaluate distribution, tissues with complete lack of staining were scored as (0); tissues prevalently negative for CX3CR1 displaying some areas of positive
staining were scored as (0–1); tissues showing uniform staining for CX3CR1 were scored as either (1–2) or (2–3), based on the intensity of the signal
observed.
Figure 1. Expression of CX3CR1 in
prostate glands from human donors.
Normal and malignant prostate glands
stain either negative (A) or show
different staining intensities and
distributions for CX3CR1 (B and C).
As previously reported by others (34),
smooth muscle cells were consistently
found positive for CX3CR1 (white arrow).
CX3CR1 expression was also detected
in tissue cores of skeletal metastases
obtained from subjects affected by
prostate adenocarcinoma (D). Original
magnification, 200.
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formation, would thereby acquire a higher propensity to locate to
fractalkine-expressing secondary tissues. The information regard-
ing the postsurgery follow-up for the donors of each prostate tissue
included in the microarrays we used was not available; there-
fore, the possible correlation between CX3CR1 expression and the
occurrence of bone secondary tumors could not be addressed
in the present study. However, we tested tissue cores of skeletal
metastases from prostate adenocarcinoma obtained from four
different donors and found them all positive for CX3CR1 expres-
sion (Fig. 1D).
According to a widely accepted model for the establishment
of metastasis, a further step following the adhesion of circulat-
ing cancer cells to the endothelial wall is their migration and
invasion into the surrounding tissue in response to chemo-
attractant molecules. We have previously shown that fractalkine
could promote in vitro migration of CX3CR1-expressing cells (17);
the production of this chemokine by bone-resident cells could
therefore play a role in the invasion of the bone tissue by prostate
cancer cells. To ascertain whether fractalkine is present in the
bone marrow, we employed tissue arrays including samples from
27 different human donors and detected the chemokine with
a signal intensity ranging from weak to moderate (Fig. 2A). The
specificity of the primary antibody was validated using cores from
human kidney tissue, which expresses fractalkine as well as liver,
which is negative for this chemokine (ref. 14; Supplementary
Data 2). Using a complementary approach, we isolated cellular
fractions from bone marrow aspirates and detected the membrane-
associated form of the chemokine by Western blotting (Fig. 2B,
top). The cleavage of the full-length form of fractalkine from
these cells would accumulate the soluble and chemoattractant form
of the chemokine into the stroma and therefore induce CX3CR1-
expressing cancer cells to extravasate into the bone marrow. To test
this idea, we measured soluble fractalkine in human bone marrow
aspirates—deprived of their cellular fraction—and found them
positive for the chemokine in concentrations averaging 2 ng/mL
(Fig. 2B, bottom). Interestingly, similar concentrations of this
chemokine induce the in vitro migration of prostate cancer
cells through a Matrigel-coated membrane (17). It should be em-
phasized that the fractalkine concentrations we measured ex vivo
necessarily represent average values, and because of the inherent
compartmentalization of the human bone marrow, it is likely
that higher levels of this chemokine may exist in selected regions
of the intact tissue.
The next series of experiments were conducted using single cell
types isolated from human bone marrow and available through a
commercial source. We used primary osteoblasts (NHOst), bone
mesenchymal stem cells (hMSC), and bone stromal cells (BSC)
and found them all positive for fractalkine expression, with BSC
expressing the most, and NHOst the least, of the full-length form
of the chemokine (Fig. 2C). In addition to the hematopoietic
cell lineage, these three cell types represent the most relevant
cellular fraction within the bone marrow microenvironment. The
fact that fractalkine is ubiquitously expressed among these cells
suggests that significant levels of this chemokine could be pro-
duced within the marrow regardless of the changes in the bone
Figure 2. Detection of both cell-bound and
soluble forms of fractalkine in human bone
marrow. A, normal bone marrow stains
positive for fractalkine expression, showing
a staining diffused throughout the entire
marrow stromal architecture. B, cells
of the bone marrow obtained from
aspirates of three human donors express
the full-length and cell-bound forms of
fractalkine when analyzed by Western
blotting. A recombinant, full-length form of
fractalkine was loaded along with the cell
lysates in the same gel and used as a
positive control (top). The supernatants of
bone marrow aspirates from five different
human donors were analyzed by ELISA
and tested positive for the soluble form
of fractalkine (bottom). C, when distinct
human bone marrow cell types were
analyzed by Western blotting, they were
all found positive for the full-length form
of fractalkine, with the lowest expression
levels detected in osteoblasts (NHOst),
the highest in BSC and hMSCs showing
intermediate levels. D, the location of
fractalkine at the plasma membrane
level was confirmed by fluorescence
confocal microscopy (white arrows)i nt h e
hMSC shown; *, a possible intracellular
storage for the chemokine (26). Original
magnification, 600.
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of each cell type, such as those occurring during bone turnover and
remodeling. The conclusive demonstration that the full-length form
of fractalkine is effectively exposed on the cell surface of bone-
resident cells was obtained by confocal microscopy; in addition,
we could also detect an intracellular staining for fractalkine, as
previously described in different cell types by others (26). This
storage compartment has been found to be involved in the recycling
of the chemokine and is responsible for its translocation to the cell
surface (Fig. 2D).
The chemokine-like domain of fractalkine is located atop a gly-
cosylated mucin-like stalk connected to a transmembrane domain
(14); its proteolytic cleavage and the ensuing ectodomain shed-
ding are largely mediated by members of MMPs (22, 23), which
are expressed by osteoblasts (19–21) and regulated by androgens
(28–30). Interestingly, circulating androgens critically affect the
clinical progression of prostate adenocarcinoma; accordingly, anti-
androgen therapeutic approaches can significantly prolong the
metastasis-free survival, as shown by a recent clinical trial (18).
This circumstantial evidence prompted us to investigate whether
the exposure of bone cells to androgens could increase the cleavage
of the cell-bound form of fractalkine; we used hMSC as they express
intermediate levels of the chemokine among the cell types tested
and also represent the precursors of the majority of cell types found
in the bone stroma. When hMSC were exposed to dihydrotestos-
terone (100 nmol/L) for 1 hour, the levels of cell surface fractalkine
were dramatically reduced; this effect was indeed exerted through
the stimulation of androgen receptors, such as the specific inhi-
bitor nilutamide (31), which fully blocked the decrease in frac-
talkine induced by dihydrotestosterone (Fig. 3A and B). The
removal of fractalkine from the cell surface after dihydrotestoster-
one exposure corresponded to its cleavage into the extracellular
space, as shown by the increased levels of the soluble form of the
chemokine in the cell supernatants after 24-hour exposure to the
androgen (Fig. 3C). The cleavage of fractalkine has been reported
as being coupled to the rapid relocation of the chemokine to the
plasma membrane from intracellular storage sites. This recycling
mechanism would finely regulate the availability of fractalkine
at the cell surface as well as support the cellular needs for an
increased release of its soluble form (26). Interestingly, we found
Figure 3. The cleavage of fractalkine from the cell surface is regulated by the androgen receptor. hMSCs from bone marrow were exposed to 100 nmol/L of
dihydrotestosterone for 1 hour with or without previous 30-minute incubations with 1 Amol/L of nilutamide. The dramatic decrease in full-length fractalkine induced by
100 nmol/L of dihydrotestosterone was completely blocked by nilutamide, whereas nilutamide alone did not significantly affect the levels of cell-bound fractalkine.
A and B, results are representative of five separate experiments (*, P < 0.05). An ELISA-based assay was used to detect the soluble form of fractalkine in hMSC
supernatants and shows that dihydrotestosterone induces the cleavage of the membrane-bound chemokine into its soluble form. C, three separate experiments
were conducted using supernatants of hMSC cells obtained from different donors and assessed in duplicate (*, P < 0.05). D, subsequently, fractalkine at the cell surface
is restored in a time-dependent fashion (top). The broad-spectrum MMP inhibitor GM6001 partially blocked the decrease in cell-bound fractalkine induced by
dihydrotestosterone, confirming that the reduction in this chemokine level is a consequence of cleavage from the cells and that MMPs are involved in this process
(bottom). For Western blotting analysis, a recombinant and full-length form of fractalkine was loaded along with the cell lysates in the same gel and used as a
positive control.
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dramatically reduced following 1 hour of dihydrotestosterone
exposure—were restored in a time-dependent manner despite the
continuous exposure of the cells to the hormone (Fig. 3D, top). It
seems plausible that this is due to an increased recycling of the
chemokine, whereas the effect exerted by dihydrotestosterone on
its cleavage is long-lasting.
A further indication that dihydrotestosterone could stimulate
the cleavage of cell-bound fractalkine was obtained by using the
broad-range MMPs inhibitor Ilomastat or GM6001 (32). This
compound was able to partially block the reduction of the frac-
talkine from the cell surface induced by dihydrotestosterone in
hMSC, thus pointing toward an involvement of MMPs in the cel-
lular cleavage of this chemokine (Fig. 3D, bottom).
An androgen-induced increase of soluble fractalkine in the bone
marrow could potentially promote the migration of CX3CR1-
bearing cancer cells toward the concentration gradient and
therefore their extravasation; however, androgens could equally
promote the cleavage of this chemokine from bone marrow
endothelial cells—which express androgen receptor (20)—thereby
impairing the adhesion of circulating prostate cancer cells to the
vascular wall of the marrow sinusoids. Therefore, the next expe-
riments were conducted to ascertain the effects of dihydrotestos-
terone on the cleavage of fractalkine from HBME cells. Fractal-
kine was detected on the surface of HBME cells by confocal
microscopy (Fig. 4A), thus confirming our previous results obtained
by conventional immunofluorescence (17). However, cell surface
fractalkine was not reduced by dihydrotestosterone exposure
and although the soluble form of the chemokine could be detected
in the supernatants of HBME cells, its levels were unaffected by
dihydrotestosterone (Fig. 4B and C). The basis for the lack of
fractalkine cleavage from HBME cells in response to androgens
could be the different involvement in the cleavage process of the
ADAM-17/TACE protease (22) in these cells as compared with
hMSC. ADAM-17 has been implicated in the inducible cleavage
of fractalkine (23), its activity is stimulated by dihydrotestoster-
one (29) and therefore would represent an ideal candidate for
the release of soluble fractalkine from hMSC. Two forms of this
metalloprotease are found in cells: a full-length precursor (120kDa)
and the mature form (100 kDa), which has been detected at
the cell surface level (28, 33). When we tested hMSC and HBME
cells for ADAM-17 expression, we found that the ratios of the
two forms of the protease were dramatically different: whereas
hMSC express higher levels of the mature ADAM-17 compared
Figure 4. Expression of fractalkine by HBME cells and lack of effect of dihydrotestosterone on its cleavage. A, confocal microscopy analysis shows that fractalkine
is expressed on the plasma membrane of HBMEcells. The exposure of these cells to 100 nmol/L of dihydrotestosterone did not affect the levels of plasma
membrane fractalkine, even after prolonged treatment. B, the results are representative of five separate experiments. C, the lack of reduction in fractalkine at the
cell surface corresponds to the absence of dihydrotestosterone-induced cleavage of the cell-bound chemokine into its soluble form, as established by an ELISA
assay performed using supernatants of HBMEcells derived from five separate experiments and assessed in duplicate. D, the premature and mature forms of ADAM-17/
TACEprotease were detected in hMSC and HBMEcells by Western blotting ( top). The hMSC express significantly higher levels of the mature ADAM-17 as
compared with the HBMEcells, which show almost exclusive expression of the premature form of the protease ( bottom).
Cancer Research
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HBME cells (Fig. 4D). The hMSC also showed higher overall levels
of mature ADAM-17 as compared with HBME cells. The negligible
expression of functional protease could therefore explain the lack
of fractalkine cleavage from HBME cells exposed to dihydrotestos-
terone.
In summary, our study shows the expression of the chemokine
receptor CX3CR1 in the epithelial cell compartment of the pro-
state gland. We also obtained the first demonstration that the
chemokine fractalkine—the only ligand for CX3CR1 (3, 4)—is
present in the bone marrow of adult human subjects. The plasma
membrane–associated form of fractalkine is detected in osteo-
blasts, mesenchymal, and stromal cells and its cleavage leads
to the accumulation of the soluble and chemoattractant form
in the acellular fraction of the marrow. This phenomenon could
produce a concentration gradient of this chemokine that is
able to chemoattract CX3CR1-bearing cells—including prostate
cancer cells—from the blood circulation and into the skeleton.
Interestingly, the exposure of cells of the bone marrow stroma
to dihydrotestosterone causes a dramatic increase in fractal-
kine cleavage. This process is blocked by nilutamide as well as
inhibitors of MMPs, indicating that fractalkine cleavage involves
an androgen receptor–dependent functional stimulation of these
enzymes.
Thus, our results point to a possible scenario in which full-length
fractalkine, exposed on the luminal side of the endothelial cells
lining the bone marrow sinusoids, provides viable docking sites for
circulating CX3CR1-expressing cancer cells (Fig. 5). Interestingly,
we found that HBME cells do not cleave the plasma membrane–
associated fractalkine in response to dihydrotestosterone in vitro;
this would indicate that these cells provide CX3CR1-bearing cancer
cells with docking sites on bone marrow sinusoids also in the
presence of circulating androgens. The adhesion and extravasation
of cancer cells are complex phenomena that depend on several
molecules in general and chemokines in particular. However, based
on our present and past studies (17), the involvement of CX3CR1-
fractalkine interactions in cancer cell adhesion to selected endo-
thelial cells seems very likely and might also participate in the
extravasation of cancer cells into the bone marrow stroma (Fig. 5).
This mechanism, based on the release of the soluble form of
fractalkine from cells of the marrow stroma, seems to involve en-
zymes of the MMP family promoted by activation of the androgen
receptor.
It should be emphasized that conclusive evidence for a deter-
minant role of the CX3CR1/fractalkine pair in skeletal metastasis
will be obtained using experimental approaches targeting these
molecules by short hairpin RNA and employing in vivo animal
models as well as transgenic knockout animals; these experiments
are currently being conducted in our laboratory. However, the
ex vivo and in vitro evidence we present in this study strongly sug-
gests that the chemokine receptor, CX3CR1, its ligand fractalkine,
and the enzymes responsible for the cleavage of this chemokine
may represent suitable targets for a therapeutic intervention aim-
ing to counteract skeletal metastasis from prostate cancer cells.
Importantly, our results suggest the existence of an androgen
receptor–dependent signaling mechanism modulating fractalkine
cleavage from bone-resident cells and possibly underlying some
of the effect of antiandrogen therapy in delaying the appearance
of skeletal secondary tumors in patients affected by prostate
adenocarcinoma.
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Figure 5. Possible roles of fractalkine and its receptor
CX3CR1 in the adhesion of circulating prostate
cancer cells to the bone marrow endothelium and their
extravasation. A, the cell-bound fractalkine expressed
on the surface of HBMEcells directly functions as an
adhesion molecule and allows CX3CR1-bearing cells to
adhere to the vascular wall of bone marrow sinusoids.
B, adherent cancer cells migrate into the marrow
stroma following the concentration gradient of soluble
fractalkine, produced and released by cells of the bone
microenvironment.
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